Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Clinical trial NCT04323436 · TERMINATED
Trial details
- NCT number
- NCT04323436
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-19
- Primary completion
- 2022-12-14
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.